GLPBio

Boc-MLF TFA

Catalog No.: GC35540Purity:>99.50%Synonyms: Boc-Met-Leu-Phe-OH (TFA)
COASDSData Sheet
Boc-MLF (TFA) est un peptide, utilisé comme antagoniste spécifique du récepteur formyl-peptide (FPR), inhibe également la signalisation via le récepteur formyl-peptide comme 1 (FPRL1) À des concentrations plus élevées.

Les produits sont exclusivement destinés à la recherche. Ils ne doivent pas être utilisés chez l’être humain. Nous ne vendons pas aux patients.

Boc-MLF TFA
1mgIn Stock
$31.00
1
5mgIn Stock
$75.00
1
10mgIn Stock
$104.00
1
25mgIn Stock
$178.00
1
50mgIn Stock
$259.00
1
100mgIn Stock
$376.00
1
200mgIn Stock
$537.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citations

Aucune citation n’est actuellement disponible pour ce produit. Vous trouverez ci-dessous une sélection de publications citant des produits GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Boc-MLF TFA is a tripeptide compound with FPR1 antagonistic activity. Boc-MLF TFA blocks fMLF binding to FPR1 and inhibits neutrophil chemotaxis, superoxide production, and primary granule exocytosis. Boc-MLF TFA inhibits FPRL1-mediated calcium response. Boc-MLF TFA is used for research on neutrophil inflammation, infection-related inflammation, and premature rupture of membranes[1-4].

In vitro, pretreatment of Neuro2a cells with 5μM Boc-MLF TFA for 30min followed by FPRa14 treatment for 48h reduced FPRa14-induced Neuro2a cell differentiation[5]. Incubation of fMLF-stimulated human neutrophils with 5-10μM Boc-MLF TFA for 5min inhibited neutrophil superoxide production[6]. Pretreatment of U87 cells with 5μM Boc-MLF TFA for 30min followed by 0.1μM fMLF stimulation for 24h. Boc-MLF TFA attenuated fMLF-induced tumorigenic chemotaxis and migration of U87 cells[7].

In vivo, intraperitoneal injection of 25mg/kg Boc-MLF TFA for 8 days in a CT26 cell xenograft BALB/c mouse model treated with neoadjuvant chemoradiotherapy reduced tumor-infiltrating CD8α+ T cells, CD8α+CD44+ T cells, and CD8α+GzmB+ TILs, and weakened the antitumor efficacy of CCRT[8]. Intraperitoneal injection of 5mg/kg Boc-MLF TFA for 2 days in a pregnant SD rat fetal membrane inflammation model promoted an increase in fetal membrane collagen, inhibited amniotic epithelial-mesenchymal transition, and repaired fetal membrane epithelial cell structure[9].

References:
[1] Stenfeldt AL, Karlsson J, Wennerås C, et al. Cyclosporin H, Boc-MLF TFA and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation. 2007 Dec;30(6):224-9.
[2] Xu XW, Zhang Y, Zhao CW, et al. Lenvatinib-resistant liver cancer-derived HSP90α-containing extracellular vesicles enhance drug resistance via macrophage CXCL8 secretion. Immunol Lett. 2026 Apr;278:107122.
[3] Gong Z, Yang C, Dai W, et al. Annexin A1 exerts analgesic effect in a mouse model of medication overuse headache. iScience. 2023 Nov 17;26(11):108153.
[4] Chiu I M, Heesters B A, Ghasemlou N, et al. Bacteria activate sensory neurons that modulate pain and inflammation. Nature. 2013 Sep 5;501(7465):52-57.
[5] Cussell P J G, Howe M S, Illingworth T A, et al. The formyl peptide receptor agonist FPRa14 induces differentiation of Neuro2a mouse neuroblastoma cells into multiple distinct morphologies which can be specifically inhibited with FPR antagonists and FPR knockdown using siRNA. PLoS ONE. 2019 Jun;14(6):e0217815.
[6] Stenfeldt A L, Karlsson J, Wenneras C, et al. Cyclosporin H, Boc-MLF TFA and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation. 2007 Dec;30(6):224-229.
[7] Bao Z, Chen K, Krepel S, et al. High glucose promotes human glioblastoma cell growth by increasing the expression and function of chemoattractant and growth factor receptors. Transl Oncol. 2019 Sep;12(9):1155-1163.
[8] Chiang S, Huang K, Chen W, et al. Polymorphism of formyl peptide receptor 1(FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy(CCRT) treatment in locally advanced rectal cancer. Cancer Immunol Immunother. 2021;70(12):2937-2950.
[9] Huang X, Liao E, Liao J, et al. FPR1 antagonist(Boc-MLF TFA) inhibits amniotic epithelial-mesenchymal transition. Current Medical Science. 2024 Feb;44(1):187-194.

Protocole (Protocol)

Cell experiment [1]:

Cell lines

 U87 cells (human glioblastoma cell line)

Preparation Method

 U87 cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% FCS at 37°C, 5% CO2 and cultured under normal glucose (5.5mM) or high glucose (25mM). U87 cells cultured in normal glucose or high glucose were pretreated with Boc-MLF TFA (5μM) for 30min before scratching, then fMLF-accelerated wound closure was measured at 24h and photographed for Image J analysis.

Reaction Conditions

 5μM; 30min pretreatment

Applications

 Boc-MLF TFA diminished fMLF-induced U87 cell chemotaxis. Boc-MLF TFA attenuated fMLF-accelerated U87 monolayer wound closure.
Animal experiment [2]:

Animal models

 Sprague-Dawley pregnant rats

Preparation Method

Pregnant rats at 15 days gestation were intraperitoneally injected with LPS (500μg/kg), and 4h later intraperitoneally injected with Boc-MLF TFA (5mg/kg) for two consecutive days. Rats were sacrificed at 17-19 days of pregnancy for collection of fetal membranes and cardiac blood for Western blotting, immunofluorescence, Masson staining, SEM, and ELISA analyses.

Dosage form

5mg/kg; i.p.; 2days

Applications

Boc-MLF TFA promoted an increase in fetal membrane collagen. Boc-MLF TFA inhibited EMT, reduced the weakening of fetal membranes, reversed LPS-induced collapse of fetal membrane epithelial cells, increased intercellular gaps, and mucus attachment, decreased IL-6 levels in cardiac blood.
References:
[1] Bao Z, Chen K, Krepel S, et al. High Glucose Promotes Human Glioblastoma Cell Growth by Increasing the Expression and Function of Chemoattractant and Growth Factor Receptors. Transl Oncol. 2019 Sep;12(9):1155-1163.
[2] Huang X, Liao E, Liao J, et al. FPR1 Antagonist(Boc-MLF TFA) Inhibits Amniotic Epithelial-mesenchymal Transition. Curr Med Sci. 2024 Feb;44(1):187-194.

Documents produit (Product Documents)

Purity:>99.50%Appearance:A solid
COASDSData Sheet

Propriétés chimiques (Chemical Properties)

Synonymes
Boc-Met-Leu-Phe-OH (TFA)
SMILES
O=C(O)[C@H](CC1=CC=CC=C1)NC([C@H](CC(C)C)NC([C@H](CCSC)NC(OC(C)(C)C)=O)=O)=O.OC(C(F)(F)F)=O
Formule moléculaire
C27H40F3N3O8S
Masse moléculaire
623.68
Solubilité
DMSO: 150 mg/mL (240.51 mM)
Conservation
Store at -20°C
Conseils généraux
Choisissez un solvant adapté selon les données de solubilité du produit. Après préparation, répartissez la solution mère en aliquotes afin d’éviter les cycles répétés de congélation-décongélation.
Utilisez les solutions mères dans les 6 mois si elles sont conservées à -80°C, ou dans le mois si elles sont conservées à -20°C.
Pour améliorer la solubilité, réchauffez le tube à 37°C et soniquez-le pendant une durée appropriée.
Conditions d’expédition
Les échantillons d’évaluation sont expédiés avec des blocs réfrigérants. Les autres formats sont expédiés à température ambiante ou, sur demande, avec des blocs réfrigérants.

Calculateurs (Calculators)Molarité / Dilution / Masse moléculaire / Conversion d’unités / Formulation in vivo / Solubilité

g/mol

Reviews

Review for Boc-MLF TFA

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%